Marker Therapeutics Update on Lymphoma Treatment Study
Marker Therapeutics, Inc. (NASDAQ: MRKR) has recently provided a significant update on its clinical development progress in the realm of lymphoma treatment. This update focuses on the Phase 1 APOLLO study that investigates MT-601, a Multi-Antigen Recognizing (MAR)-T cell product designed for patients with lymphoma who have either relapsed following anti-CD19 CAR-T cell therapy or are not candidates for this type of treatment.
Clinical Study Overview
The company restructured its clinical programs last year, with a particular emphasis on prioritizing MT-601. This strategic decision reflects their commitment to developing advanced cellular therapies that can potentially transform lymphoma treatment.
Safety and Efficacy Results
Recent updates from the study indicate a favorable safety profile across various doses (ranging from 100×106 to 400×106 cells) for the treatment of patients with Non-Hodgkin Lymphoma (NHL). Specifically, the objective response rate was reported at an impressive 66%, with half of those evaluated achieving complete response (CR).
In total, 24 patients with B-cell lymphoma were treated using MT-601, with 15 patients having NHL and nine diagnosed with Hodgkin Lymphoma (HL). As of the most recent data cutoff, 12 NHL and nine HL patients have been thoroughly evaluated, and the safety data collected substantiates a robust safety profile, with no serious adverse events reported.
Detailed Efficacy Observations
Among the 12 NHL patients treated with doses between 100×106 and 200×106 cells, 66% exhibited objective responses, signifying the treatment's effectiveness in this patient cohort. Notably, durable responses were observed for a duration of three to 24 months. Five subjects even demonstrated ongoing responses lasting six months or longer, with three crossing the 12-month threshold.
Conversely, the HL patients received doses between 200×106 to 400×106 cells. Among the nine treated, seven achieved objective responses, translating to a response rate of 78%. This highlights the versatility of the MT-601 treatment across various lymphoma types.
Robust Safety Record
The safety data collected during the dose escalation trials indicates no dose-limiting toxicities (DLTs) at the highest administered dosage of 400×106 cells, fostering optimism regarding patient tolerability. All participants tolerated the infusion of MT-601 well, with only minor Grade 1 cytokine release syndrome (CRS) events reported.
Furthermore, the analysis showed no significant differences in DLTs or immune effector cell-associated neurotoxicity syndrome (ICANS) among patients treated with or without preceding lymphodepleting chemotherapy before receiving MT-601 infusions. This suggests that the treatment can be administered effectively regardless of prior therapy.
Future Development and Company Outlook
Looking ahead, Marker Therapeutics aims to provide further updates on study outcomes in the first half of 2026, keeping stakeholders informed on ongoing developments. As of the latest information, the stock price for Marker Therapeutics was reported at $1.08, reflecting a decline of 14.28% at that time.
Frequently Asked Questions
What is MT-601?
MT-601 is a Multi-Antigen Recognizing (MAR)-T cell therapy developed by Marker Therapeutics for the treatment of lymphoma patients.
How effective is MT-601 based on recent studies?
Recent studies show a 66% objective response rate in patients with Non-Hodgkin Lymphoma, with 50% achieving full remission.
What is the safety profile of MT-601?
The safety profile indicates no dose-limiting toxicities at the highest doses, with a generally well-tolerated infusion experience among participants.
Can patients with Hodgkin Lymphoma use MT-601?
Yes, nine patients with Hodgkin Lymphoma were included in the trial, with a 78% objective response rate reported.
When can we expect more data from Marker Therapeutics?
The company plans to release further updates regarding the study results in the first half of 2026.
